Aktueller Stellenwert von Fluorchinolonen in der Helicobacter-pylori-Therapie
Standard
Aktueller Stellenwert von Fluorchinolonen in der Helicobacter-pylori-Therapie. / Krasz, S; Miehlke, S; Berning, M; Morgner, A; Labenz, J.
in: Z GASTROENTEROL, Jahrgang 49, Nr. 8, 08.2011, S. 989-96.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Aktueller Stellenwert von Fluorchinolonen in der Helicobacter-pylori-Therapie
AU - Krasz, S
AU - Miehlke, S
AU - Berning, M
AU - Morgner, A
AU - Labenz, J
N1 - © Georg Thieme Verlag KG Stuttgart · New York.
PY - 2011/8
Y1 - 2011/8
N2 - Eradication rates in first-line Helicobacter pylori therapy have been declining over the last decades, mainly due to increasing resistance against the recommended antibiotics clarithromycin and metronidazole. Thus, there is a need to evaluate novel regimens and substances to offer effective alternative treatment strategies. New generation quinolones, like levofloxacin and moxifloxacin, exhibit a broad-spectrum activity against various Gram-positive and Gram-negative strains and are mostly well tolerated. Based on a large number of studies, quinolones have been introduced in second-line and rescue treatment and are recommended for these indications in current guidelines. Various studies have investigated alternative strategies for first-line treatment including quinolone-based regimens. In the context of increasing resistance rates of Helicobacter pylori against quinolones some risks and benefits have to be considered when using quinolones as a first-line strategy. Besides numerous studies investigating levofloxacin and moxifloxacin there are some promising results for the new substance sitafloxacin, which might overcome primary resistance of Helicobacter pylori against conventional quinolones.
AB - Eradication rates in first-line Helicobacter pylori therapy have been declining over the last decades, mainly due to increasing resistance against the recommended antibiotics clarithromycin and metronidazole. Thus, there is a need to evaluate novel regimens and substances to offer effective alternative treatment strategies. New generation quinolones, like levofloxacin and moxifloxacin, exhibit a broad-spectrum activity against various Gram-positive and Gram-negative strains and are mostly well tolerated. Based on a large number of studies, quinolones have been introduced in second-line and rescue treatment and are recommended for these indications in current guidelines. Various studies have investigated alternative strategies for first-line treatment including quinolone-based regimens. In the context of increasing resistance rates of Helicobacter pylori against quinolones some risks and benefits have to be considered when using quinolones as a first-line strategy. Besides numerous studies investigating levofloxacin and moxifloxacin there are some promising results for the new substance sitafloxacin, which might overcome primary resistance of Helicobacter pylori against conventional quinolones.
KW - Anti-Bacterial Agents
KW - Aza Compounds
KW - Drug Resistance, Bacterial
KW - Drug Therapy, Combination
KW - Fluoroquinolones
KW - Helicobacter Infections
KW - Helicobacter pylori
KW - Humans
KW - Levofloxacin
KW - Microbial Sensitivity Tests
KW - Ofloxacin
KW - Quinolines
KW - English Abstract
KW - Journal Article
KW - Review
U2 - 10.1055/s-0031-1273390
DO - 10.1055/s-0031-1273390
M3 - SCORING: Zeitschriftenaufsatz
C2 - 21811951
VL - 49
SP - 989
EP - 996
JO - Z GASTROENTEROL
JF - Z GASTROENTEROL
SN - 0044-2771
IS - 8
ER -
